Madrigal Pharmaceuticals (MDGL) Non-Current Assets (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Non-Current Assets data on file, last reported at $45.0 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $45.0 million, up 420.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.6 million (up 143.17% YoY), and the FY2025 annual result was $13.8 million, up 48.27% from the prior year.
• Non-Current Assets climbed to $45.0 million in Q1 2026 per MDGL's latest filing, from $13.8 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $45.0 million in Q1 2026 and troughed at $866000.0 in Q2 2023.
• A 5-year average of $8.5 million and a median of $8.1 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2023 and 2024: Non-Current Assets tumbled 53.09% in 2023, then soared 830.83% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $1.2 million in 2022, then jumped by 171.49% to $3.3 million in 2023, then surged by 185.36% to $9.3 million in 2024, then surged by 48.27% to $13.8 million in 2025, then soared by 225.78% to $45.0 million in 2026.
• Business Quant data shows MDGL's Non-Current Assets at $45.0 million in Q1 2026, $13.8 million in Q4 2025, and $15.8 million in Q3 2025.